Werewolf Therapeutics Inc
HOWLHealthcare·Biotechnology·USA·Nano·NASD·Nov 13 • 8:16 AM ET
1.01+0.03 (3.06%)
2026-11-13 14:25 CET
Market cap
$49.09M
Revenue, TTM
21.00 USD m
Net income, TTM
-34.61 USD m
Free cash flow, TTM
-30.15 USD m
EPS diluted, TTM
-0.74
Price
HOWL against its 20, 50 and 200-day averagesPatternshover a marker to name it
15.8% under the 52-week high of 1.20 on 17 Dec 2025. 52-week low 0.27 on 29 Jun 2026. Last 15 sessions, 15.8% high to low
Volume 0.00× normal · the line is the 50-bar volume average
Setup. RS line 23
CANSLIM 3 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%; Institutional Ownership: Over 50%
VCP 5 of 6 — fails: 52-Week High/Low: 0-10% below High
Minervini 2 of 4 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 2 of 5 — fails: Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 3 of 5 — fails: Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 3 of 4 — fails: Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 1 of 4 — fails: P/B: Under 2; Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 3 of 4 — fails: Performance: Year +50%
Accumulation 3 of 4 — fails: Institutional Ownership: Over 30%
Relative Strength 2 of 3 — fails: Performance: Year +100%
Profile
HOWL52-week range, 80% of the way up
0.271.20
Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The firm offers Predator Technology which focuses on immune targeting and activation. The company was founded by Daniel J. Hicklin, Patrick A. Baeuerle, and Luke B. Evnin on October 19, 2017 and is headquartered in Watertown, MA.
| Employees | 39 |
|---|---|
| IPO | Apr 30, 2021 |
| Beta | 0.55 |
| ATR, 14d | 0.05 |
| Rel volume | 0.00 |
| Short float | 5.33% |
| Insider own | 17.84% |
| Inst own | 22.67% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | $49.09M |
| Enterprise Value | 27.10M |
| Income | -34.61M |
| Sales | 21.00M |
| Book / share | 0.34 |
| Cash / share | 0.45 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 39 |
| IPO | Apr 30, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 2.34 |
| Price / book | 3.01 |
| Price / cash | 2.23 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 1.29 |
| Quick Ratio | 2.91 |
| Current Ratio | 2.91 |
| Debt / equity | 0.00 |
| Long-term debt / equity | 0.00 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.74 |
|---|---|
| Earnings next year | -0.59 |
| Earnings next quarter | -0.22 |
| Earnings this year | 33.08% |
| Earnings next year | 33.71% |
| Earnings growth, 5 years | - |
| Past earnings growth | 10.71% -6.15% |
| Past sales growth | - - |
| Earnings vs last year | 55.37% |
| Sales vs last year | -100.00% |
| Earnings vs last quarter | 118.88% |
| Sales vs last quarter | - |
| Earnings | Jul 31 BMO |
| Surprise | - - |
Ownership
| Insiders own | 17.84% |
|---|---|
| Insider trades | -22.78% |
| Institutions own | 22.67% |
| Institution trades | 27.27% |
| Return on assets | -59.31% |
| Return on equity | -119.86% |
| Return on capital | -212.45% |
| Gross Margin | 82.61% |
| Operating margin | -121.78% |
| Profit Margin | -164.82% |
| 20-day average | -1.35% |
| 50-day average | 2.65% |
| 200-day average | 44.13% |
Technical
| Shares out | 48.60M |
|---|---|
| Shares floating | 39.93M |
| Short / float | 5.33% |
| Short ratio | 0.32 |
| Short interest | 2.13M |
| 52-week high | 1.20 -15.8% |
| 52-week low | 0.27 +274.1% |
| Volatility | 4.29% 5.80% |
| Average range | 0.05 |
| Strength index | 51.59 |
| Market sensitivity | 0.55 |
| Relative volume | 0.00 |
| Avg Volume | 6.58M |
| Volume | 509 |
Performance
| Perf Week | 0.00% |
|---|---|
| Perf Month | 1.30% |
| Perf Quarter | 149.08% |
| Perf Half Y | 96.08% |
| Perf YTD | 59.43% |
| Perf Year | 8.87% |
| Perf 3Y | -54.50% |
| Perf 5Y | -93.70% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 4.00 |
| Prev Close | 0.98 |
| Price | 1.01 |
| Change % | 3.06% |
Analyst ratings
latest 9 of 9| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Dec 19, 2025 | Downgrade | Wedbush | Outperform → Neutral | $1 | -1.0% |
| Apr 03, 2024 | Initiated | JMP Securities | Mkt Outperform | $12 | +1,088.1% |
| Aug 24, 2023 | Initiated | Wedbush | Outperform | $9 | +791.1% |
| Jun 06, 2023 | Resumed | Jefferies | Buy | $11 → $12 | +1,088.1% |
| Sep 10, 2021 | Initiated | BofA Securities | Buy | $26 | +2,474.3% |
| May 25, 2021 | Initiated | SVB Leerink | Outperform | $29 | +2,771.3% |
| May 25, 2021 | Initiated | Jefferies | Buy | $22 | +2,078.2% |
| May 25, 2021 | Initiated | H.C. Wainwright | Buy | $32 | +3,068.3% |
| May 25, 2021 | Initiated | Evercore ISI | Outperform | $23 | +2,177.2% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| XLO | Xilio Therapeutics Inc | 58.21M |
| CTMX | CytomX Therapeutics Inc | 444.73M |
| HCWB | HCW Biologics Inc | 1.79M |
| BOLT | Bolt Biotherapeutics Inc | 11.38M |
| JANX | Janux Therapeutics Inc | 709.72M |
| NKTR | Nektar Therapeutics | 1.24B |
| STTK | Shattuck Labs Inc | 489.86M |
| ALXO | Alx Oncology Holdings Inc | 152.11M |
| GTBP | GT Biopharma Inc | 7.87M |
| IMNN | Imunon Inc | 3.29M |
Insider trading
latest 14 of 100| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director | Jul 07 '26 | Sale | 0.31 | 107,429 | 33,303 | 0 | Jul 08 05:34 PM |
| EVNIN LUKE | Director | Jul 06 '26 | Sale | 0.32 | 35,770 | 11,446 | 107,429 | Jul 08 05:34 PM |
| MPM Oncology Innovations Fund, | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 21,194 | 7,214 | Jul 06 05:19 PM | |
| MPM Asset Management Investors | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 3,332 | 1,134 | Jul 06 05:19 PM | |
| MPM Asset Management LLC | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 15,341 | 5,222 | Jul 06 05:19 PM | |
| UBS Oncology Impact Fund, L.P. | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 80,142 | 27,280 | Jul 06 05:18 PM | |
| MPM BioVentures 2014 (B), L.P. | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 6,459 | 2,199 | Jul 06 05:18 PM | |
| MPM BioVentures 2014, L.P. | Shareholder | Jul 06 '26 | Proposed Sale | 0.34 | 96,873 | 32,976 | Jul 06 05:18 PM | |
| MPM Oncology Innovations Fund, | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 23,248 | 7,509 | Jun 29 05:30 PM | |
| MPM Asset Management Investors | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 3,657 | 1,181 | Jun 29 05:30 PM | |
| MPM Asset Management LLC | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 16,830 | 5,436 | Jun 29 05:29 PM | |
| UBS Oncology Impact Fund, L.P. | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 87,916 | 28,397 | Jun 29 05:29 PM | |
| MPM BioVentures 2014 (B), L.P. | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 7,087 | 2,289 | Jun 29 05:29 PM | |
| MPM BioVentures 2014, L.P. | Shareholder | Jun 29 '26 | Proposed Sale | 0.32 | 106,262 | 34,323 | Jun 29 05:29 PM |
Held by
AUMNews
latest 14 of 200- Werewolf Therapeutics' Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting (GlobeNewswire)
- Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 2026 Annual Meeting (GlobeNewswire) -10.35%
- Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders? (PR Newswire)
- Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders? (PR Newswire)
- Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing (InvestorsHub) +102.57%
- Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement (GlobeNewswire)
- Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates (GlobeNewswire) -29.44%
- Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates (GlobeNewswire) +9.68%
- Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates (GlobeNewswire) -9.54%
- Werewolf Therapeutics Announces Plan to Explore Strategic Alternatives (GlobeNewswire)
- Werewolf Therapeutics (HOWL) Eyes 2026 Catalysts Following FDA Guidance and Encouraging INDUKINE Results (Insider Monkey)
- Werewolf Therapeutics Announces Pipeline and Business Updates (GlobeNewswire) -39.57%
- Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know (Zacks) -6.36%
- Werewolf Therapeutics Presents Data Expanding Its PREDATOR Platform at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting (GlobeNewswire)
Quarterly earnings
2026Q2 EPS 0.080, from -0.400 a year earlier. Sales 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-07-31 08:30 | 0.080 | - | -0.230 | 0.00 | - | EPS - · sales - | vs 2025Q2, year-ago quarter · EPS -120.0% · sales - | - | Open -0.08% vs SPY +0.40%. Close -29.44% vs SPY +0.72% |
| 2026Q1ended 2026-03-31 | 2026-05-07 16:30 | -0.280 | - | -0.284 | 0.00 | - | EPS - · sales - | vs 2025Q1, year-ago quarter · EPS -30.0% · sales - | - | Open -0.27% vs SPY +0.46%. Close +9.68% vs SPY +0.83% |
| 2025Q4ended 2025-12-31 | 2026-03-27 08:30 | -0.200 | -0.345 | -0.173 | 0.00 | 0.00 | EPS -42.0% · sales - | vs 2024Q4, year-ago quarter · EPS -56.5% · sales - | 4 EPS · 3 sales | Open -2.68% vs SPY -0.40%. Close -9.54% vs SPY -1.71% |
| 2025Q3ended 2025-09-30 | 2025-11-04 08:30 | -0.360 | -0.383 | -0.357 | 0.00 | 0.00 | EPS -6.1% · sales - | vs 2024Q3, year-ago quarter · EPS -5.3% · sales - | 6 | Open -3.82% vs SPY -1.06%. Close -7.63% vs SPY -1.19% |
| 2025Q2ended 2025-06-30 | 2025-08-14 08:30 | -0.400 | -0.468 | -0.400 | 0.00 | 0.00 | EPS -14.5% · sales - | vs 2024Q2, year-ago quarter · EPS -7.0% · sales -100.0% | 5 | Open +1.48% vs SPY -0.33%. Close -2.22% vs SPY +0.01% |
| 2025Q1ended 2025-03-31 | 2025-05-08 08:30 | -0.400 | -0.395 | -0.404 | 0.00 | 0.00 | EPS +1.3% · sales - | vs 2024Q1, year-ago quarter · EPS +2.6% · sales -100.0% | 5 EPS · 4 sales | Open +0.17% vs SPY +0.73%. Close -5.54% vs SPY +0.70% |
| 2024Q4ended 2024-12-31 | 2025-03-11 08:30 | -0.460 | -0.403 | -0.459 | 0.00 | 0.30 | EPS +14.1% · sales -100.0% | vs 2023Q4, year-ago quarter · EPS +39.4% · sales -100.0% | 6 | Open +0.41% vs SPY -0.21%. Close +2.86% vs SPY -0.83% |
| 2024Q3ended 2024-09-30 | 2024-11-07 08:30 | -0.380 | -0.405 | -0.382 | 0.00 | 0.71 | EPS -6.2% · sales -100.0% | vs 2023Q3, year-ago quarter · EPS +65.2% · sales -100.0% | 6 | Open -2.46% vs SPY +0.35%. Close -8.20% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-08 08:30 | -0.430 | -0.376 | -0.396 | 1.14 | 0.84 | EPS +14.3% · sales +35.8% | vs 2023Q2, year-ago quarter · EPS +207.1% · sales -85.9% | 5 | Open +4.68% vs SPY +1.01%. Close +8.19% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-03 08:30 | -0.390 | -0.342 | -0.389 | 0.74 | 1.46 | EPS +14.0% · sales -49.1% | vs 2023Q1, year-ago quarter · EPS +14.7% · sales -83.4% | 5 | Open +0.82% vs SPY +1.21%. Close -0.16% vs SPY +1.24% |
| 2023Q4ended 2023-12-31 | 2024-03-07 08:30 | -0.330 | -0.424 | -0.328 | 1.50 | 1.94 | EPS -22.2% · sales -22.8% | vs 2022Q4, year-ago quarter · EPS -15.4% · sales -79.4% | 5 | Open -0.43% vs SPY +0.67%. Close -3.98% vs SPY +0.99% |
| 2023Q3ended 2023-09-30 | 2023-11-14 16:30 | -0.230 | -0.386 | -0.232 | 5.90 | 1.59 | EPS -40.4% · sales +270.6% | vs 2022Q3, year-ago quarter · EPS -42.5% · sales +18.7% | 5 | Open +0.45% vs SPY +0.31%. Close 0.00% vs SPY +0.21% |
| 2023Q2ended 2023-06-30 | 2023-08-10 08:30 | -0.140 | -0.422 | -0.143 | 8.08 | 3.15 | EPS -66.8% · sales +156.5% | vs 2022Q2, year-ago quarter · EPS -73.6% · sales +94.8% | 5 | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 08:30 | -0.340 | -0.480 | -0.345 | 4.46 | 2.03 | EPS -29.2% · sales +119.5% | vs 2022Q1, year-ago quarter · EPS -39.3% · sales - | 4 EPS · 3 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-23 08:30 | -0.390 | -0.546 | -0.388 | 7.28 | 2.07 | EPS -28.6% · sales +251.5% | vs 2021Q4, year-ago quarter · EPS -40.9% · sales - | 5 EPS · 4 sales | - |
| 2022Q3ended 2022-09-30 | 2022-11-10 08:30 | -0.400 | -0.588 | -0.401 | 4.97 | 3.05 | EPS -31.9% · sales +63.0% | vs 2021Q3, year-ago quarter · EPS -21.6% · sales - | 4 | - |
Annual earnings
2025FY EPS -1.330 beat -1.505, from -1.630 a year earlier. Sales 1.90 beat 0.00, from 1.92 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2029FYestimate | - | -0.985 | - | - | 18.00 | - |
| 2028FYestimate | - | -1.470 | - | - | 0.05 | - |
| 2027FYestimate | - | -0.590 | - | - | 0.00 | - |
| 2026FYestimate | - | -0.890 | - | - | 0.00 | - |
| 2025FY | -1.330 | -1.505 | -1.630 | 1.90 | 0.00 | - |
| 2024FY | -1.630 | -1.497 | -1.634 | 1.92 | 1.88 | - |
| 2023FY | -1.050 | -1.110 | -1.048 | 19.94 | 20.37 | - |
| 2022FY | -1.860 | -2.078 | -1.864 | 16.40 | 11.86 | - |
| 2021FY | -10.940 | -6.320 | -7.393 | 0.00 | 0.00 | - |
| 2020FY | -8.895 | - | -0.984 | 0.00 | - | - |
Quarterly results
2026Q2 revenue 21.00, from 0.00 a year earlier. Operating margin 40.7%
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026Q3 E -0.22 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026Q3 | E | per share | 2026-08-21 | -0.22 | 0.0% |
| 2026FY | R | per share | 2026-08-21 | -0.89 | -40.3% |
| 2026Q3 | R | per share | 2026-08-21 | -0.22 | -41.3% |
| 2026FY | S | per share | 2026-08-21 | 0.00 | - |
| 2026Q3 | S | per share | 2026-08-21 | 0.00 | - |
| 2025FY | E | per share | 2026-03-27 | -1.51 | 0.0% |
| 2025Q4 | E | per share | 2026-03-27 | -0.35 | 0.0% |
| 2026FY | E | per share | 2026-03-27 | -0.89 | -35.2% |
| 2026Q1 | E | per share | 2026-03-27 | -0.27 | -20.6% |
| 2026Q2 | E | per share | 2026-03-27 | -0.28 | -19.4% |
| 2025FY | S | per share | 2026-03-27 | 0.00 | - |
| 2025Q4 | S | per share | 2026-03-27 | 0.00 | - |
| 2026Q1 | S | per share | 2026-03-27 | 0.00 | - |
| 2025FY | R | per share | 2026-02-26 | -1.51 | -0.8% |
| 2025Q4 | R | per share | 2026-02-26 | -0.35 | -3.3% |
| 2026Q1 | R | per share | 2026-02-26 | -0.35 | +4.5% |
| 2026Q2 | R | per share | 2026-02-26 | -0.36 | +3.4% |
| 2026Q2 | S | per share | 2026-02-26 | 0.00 | - |
| 2025Q3 | E | per share | 2025-11-03 | -0.38 | 0.0% |
| 2025Q3 | R | per share | 2025-10-28 | -0.37 | 0.0% |
| 2025Q3 | S | per share | 2025-10-01 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-10 | -0.47 | 0.0% |
| 2025Q2 | R | per share | 2025-07-31 | -0.49 | -3.0% |
| 2025Q2 | S | per share | 2025-06-19 | 0.00 | - |
| 2025Q1 | E | per share | 2025-05-02 | -0.39 | +0.2% |
| 2025Q1 | R | per share | 2025-03-28 | -0.43 | +6.3% |
| 2025Q1 | S | per share | 2025-03-11 | 0.00 | -100.0% |
| 2024FY | E | per share | 2025-01-31 | -1.50 | -2.5% |
| 2024Q4 | E | per share | 2025-01-31 | -0.40 | -2.8% |
| 2024FY | R | per share | 2025-01-31 | -1.53 | -2.4% |
| 2024Q4 | R | per share | 2025-01-31 | -0.43 | -2.3% |
| 2024FY | S | per share | 2025-01-26 | 1.88 | 0.0% |
| 2024Q4 | S | per share | 2025-01-26 | 0.30 | 0.0% |
| 2024Q3 | E | per share | 2024-10-23 | -0.41 | 0.0% |
| 2024Q3 | R | per share | 2024-10-23 | -0.40 | 0.0% |
| 2024Q3 | S | per share | 2024-10-23 | 0.71 | 0.0% |
| 2024Q2 | E | per share | 2024-07-22 | -0.38 | 0.0% |
| 2024Q2 | R | per share | 2024-07-22 | -0.36 | 0.0% |
| 2024Q2 | S | per share | 2024-07-22 | 0.84 | 0.0% |
| 2024Q1 | E | per share | 2024-04-02 | -0.34 | +0.6% |
| 2024Q1 | S | per share | 2024-04-02 | 1.46 | -20.0% |
| 2024Q1 | R | per share | 2024-03-15 | -0.36 | +7.5% |
| 2023FY | E | per share | 2024-02-08 | -1.11 | +1.4% |
| 2023FY | R | per share | 2024-02-08 | -1.15 | +0.6% |
| 2023FY | S | per share | 2024-02-08 | 20.37 | -1.7% |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.636 | -0.984 | -7.393 | -1.864 | -1.048 | -1.634 | -1.327 | -0.7385 | - |
| Sales USD millions | 0 | 0 | 0 | 16 | 20 | 2 | 0 | 21 | - |
| Shares million shares | 29 | 29 | 27 | 31 | 39 | 45 | 49 | - | 49 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.396 | -0.382 | -0.459 | -0.404 | -0.4 | -0.357 | -0.173 | -0.284 | 0.076 |
| Sales USD millions | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 21 |
| Shares million shares | 44 | 44 | 45 | 45 | 45 | 47 | 49 | 49 | 49 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.00 | 0.00-100.0% | 1.89-90.5% | 19.94+21.6% | 16.40 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 3.65 | 1.63-9.9% | 1.81+2.8% | 1.76-29.9% | 2.51+243.8% | 0.73-6.4% | 0.78+69.6% | 0.46 |
| Gross Profit | 17.35 | -1.63-2428.6% | 0.07-99.6% | 18.18+30.9% | 13.89 | -0.73 | -0.78 | -0.46 |
| Selling, General and Administrative Excl. Other | 42.92 | 59.04-19.9% | 73.67+25.5% | 58.68-16.1% | 69.95+41.7% | 49.35+128.2% | 21.63+128.4% | 9.47 |
| Research and Development | 29.43 | 44.83-20.6% | 56.43+35.1% | 41.78-22.3% | 53.76+52.4% | 35.27+112.0% | 16.64+162.5% | 6.34 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -25.57 | -60.68 | -73.59 | -40.50 | -56.06 | -50.09 | -22.40 | -9.94 |
| Interest Expense | 4.55 | 5.27+13.1% | 4.66+48.4% | 3.14 | 0.00 | 0.00 | 0.00-100.0% | 0.37 |
| Unusual Expense | 6.45 | -2.07 | -1.07-203.9% | 1.03 | -0.56 | 0.00 | -7.30 | -0.12 |
| Net Income Before Taxes | -34.61 | -60.82 | -70.52 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -34.61 | -60.82 | -70.52 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Net Income From Continuing Operations | -34.61 | -60.82 | -70.52 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Net Income | -34.61 | -60.82 | -70.52 | -37.37 | -53.81 | -201.93 | -28.22 | -18.23 |
| EPS (Recurring) per share | -0.63 | -1.36 | -1.65 | -1.03 | -1.88 | -7.39 | -1.16 | -0.64 |
| EPS (Basic, Before Extraordinaries) per share | -0.73 | -1.32 | -1.63 | -1.05 | -1.86 | -7.39 | -0.98 | -0.64 |
| EPS (Diluted) per share | -0.74 | -1.33 | -1.63 | -1.05 | -1.86 | -7.39 | -0.98 | -0.64 |
| EBITDA | -21.92 | -59.04 | -71.78 | -38.74 | -53.55 | -49.35 | -21.63 | -9.47 |
| Non-Operating Income (Expense) | 1.96 | 3.06-54.1% | 6.67-8.6% | 7.30+332.0% | 1.69+1590.0% | 0.10+66.7% | 0.06 | -0.06 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 3.54 | 6.25-29.2% | 8.83+10.2% | 8.01+8.2% | 7.40+80.9% | 4.09+549.2% | 0.63+12.5% | 0.56 |
| Price To Sales Ratio ratio | 0.83 | - | 34.44 | 6.90 | 3.61 | - | - | - |
| Gross Margin % | 82.61 | - | 3.77 | 91.15 | 84.70 | - | - | - |
| Operating Margin % | -121.78 | - | -3,904.19 | -203.09 | -341.78 | - | - | - |
| Net Margin % | -164.82 | - | -3,740.85 | -187.37 | -328.09 | - | - | - |
| Shares Outstanding million shares | 48.60 | 48.60+8.4% | 44.83+14.6% | 39.11+24.4% | 31.43+15.1% | 27.31-4.7% | 28.660.0% | 28.66 |
| Market Capitalization | 47.63 | 47.63-27.8% | 65.95-52.8% | 139.70+121.6% | 63.03-80.8% | 328.47-2.3% | 336.19 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 21.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Cost of Goods Sold Incl. D&A | 2.45+497.6% | 0.40-7.0% | 0.40-9.1% | 0.40-11.1% | 0.41-8.9% | 0.43-6.5% | 0.44-4.3% | 0.450.0% |
| Gross Profit | 18.55 | -0.40 | -0.40 | -0.40 | -0.41-159.4% | -0.43-253.6% | -0.44-142.3% | -0.45-108.3% |
| Selling, General and Administrative Excl. Other | 10.01-41.6% | 8.57-51.2% | 9.02-54.7% | 15.32-8.1% | 17.14-12.8% | 17.57+0.7% | 19.91+42.2% | 16.67+13.4% |
| Research and Development | 5.74-56.3% | 5.12-61.0% | 6.93-55.9% | 11.63-7.2% | 13.14-13.9% | 13.12+1.6% | 15.73+63.0% | 12.53+15.6% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | 8.54 | -8.97 | -9.42 | -15.73 | -17.54 | -17.99 | -20.35 | -17.12 |
| Interest Expense | 0.47-63.8% | 1.37+8.7% | 1.37+7.9% | 1.34+8.1% | 1.30+14.0% | 1.26+26.0% | 1.27+2.4% | 1.24+37.8% |
| Unusual Expense | 4.70 | 3.63 | -1.85 | -0.03-130.0% | -0.02-100.9% | -0.17 | -3.34-262.1% | 0.10 |
| Net Income Before Taxes | 3.67 | -13.53 | -8.38 | -16.37 | -17.98 | -18.09 | -20.40 | -16.67 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | 3.67 | -13.53 | -8.38 | -16.37 | -17.98 | -18.09 | -20.40 | -16.67 |
| Net Income From Continuing Operations | 3.67 | -13.53 | -8.38 | -16.37 | -17.98 | -18.09 | -20.40 | -16.67 |
| Net Income | 3.67 | -13.53 | -8.38 | -16.37 | -17.98 | -18.09 | -20.40 | -16.67 |
| EPS (Recurring) per share | 0.14 | -0.23 | -0.20 | -0.36 | -0.40 | -0.41 | -0.51 | -0.38 |
| EPS (Basic, Before Extraordinaries) per share | 0.08 | -0.28 | -0.17 | -0.36 | -0.40 | -0.40 | -0.46 | -0.38 |
| EPS (Diluted) per share | 0.08 | -0.28 | -0.17 | -0.36 | -0.40 | -0.40 | -0.46 | -0.38 |
| EBITDA | 10.99 | -8.57 | -9.02 | -15.32 | -17.14 | -17.57 | -19.91 | -16.67 |
| Non-Operating Income (Expense) | 0.31-63.1% | 0.43-56.6% | 0.55 | 0.67-62.6% | 0.84-83.2% | 0.99-49.7% | -2.12-149.8% | 1.79-4.3% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.42-76.5% | 0.93-53.7% | 1.21-36.6% | 0.97-51.7% | 1.79-31.2% | 2.01-13.0% | 1.91+2.1% | 2.01-4.3% |
| Price To Sales Ratio ratio | 0.83 | - | - | - | - | 38.13 | 34.92 | 27.36 |
| Gross Margin % | 88.32 | - | - | - | - | - | - | - |
| Operating Margin % | 40.65 | - | - | - | - | - | - | - |
| Net Margin % | 17.48 | - | - | - | - | - | - | - |
| Shares Outstanding million shares | 48.60+7.2% | 48.60+8.4% | 48.60+8.4% | 47.27+8.1% | 45.34+3.8% | 44.83+3.6% | 44.83+14.6% | 43.72+22.6% |
| Market Capitalization | 47.63-2.6% | 40.46-7.2% | 30.75-53.4% | 90.09-2.8% | 48.91-53.9% | 43.58-84.3% | 65.95-52.8% | 92.65+21.4% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 57.05-48.6% | 111.00-17.4% | 134.34+3.9% | 129.31-18.0% | 157.63+70.3% | 92.57+417.2% | 17.90 |
| Short Term Receivables | 0.00 | 0.00-100.0% | 1.35-80.5% | 6.93 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 1.54-25.6% | 2.07-22.8% | 2.68-32.3% | 3.96+15.1% | 3.44+911.8% | 0.34+100.0% | 0.17 |
| Total Current Assets | 58.59-48.2% | 113.07-18.3% | 138.37-1.3% | 140.20-13.0% | 161.07+73.4% | 92.91+414.5% | 18.06 |
| Net Property, Plant & Equipment | 9.90-19.6% | 12.32-17.0% | 14.85-14.9% | 17.45+6.9% | 16.32+423.1% | 3.12-8.5% | 3.41 |
| Total Investments and Advances | 0.90-26.2% | 1.22-94.2% | 21.02+1637.2% | 1.210.0% | 1.21+476.2% | 0.210.0% | 0.21 |
| Intangible Assets | - | - | - | - | - | 0.00 | 0.00 |
| Deferred Tax Assets | - | 2.57 | - | - | - | - | - |
| Other Assets | 0.01-96.9% | 0.32-45.8% | 0.59-57.2% | 1.38+112.3% | 0.65+333.3% | 0.15 | 0.00 |
| Total Assets | 69.40-46.4% | 129.50-25.9% | 174.83+9.1% | 160.25-10.6% | 179.25+85.9% | 96.40+344.6% | 21.68 |
| Short Term Debt Incl. Current Port. of LT Debt | 29.99+1822.4% | 1.56-81.2% | 8.28+298.1% | 2.08+94.4% | 1.07+57.4% | 0.68+15.3% | 0.59 |
| Accounts Payable | 0.75-75.3% | 3.04+126.9% | 1.34+9.8% | 1.22-40.2% | 2.04+100.0% | 1.02+61.9% | 0.63 |
| Other Current Liabilities | 5.41-48.9% | 10.59+8.4% | 9.77-52.8% | 20.68+135.8% | 8.77+144.3% | 3.59+337.8% | 0.82 |
| Total Current Liabilities | 36.15+138.1% | 15.18-21.7% | 19.38-19.2% | 23.99+102.1% | 11.87+124.8% | 5.28+158.8% | 2.04 |
| Long Term Debt | 7.68-78.4% | 35.53-18.6% | 43.65+246.4% | 12.60-13.6% | 14.59+684.4% | 1.86-81.1% | 9.84 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | 2.57 | - | - | - | - | - |
| Other Liabilities | 0.76-73.1% | 2.83+558.1% | 0.43-67.4% | 1.32 | 0.00-100.0% | 0.03+50.0% | 0.02 |
| Total Liabilities | 44.59-20.5% | 56.11-11.6% | 63.46+67.4% | 37.91+43.3% | 26.46+268.5% | 7.18-39.7% | 11.91 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 141.08+314.1% | 34.07 |
| Common Equity | 24.80-66.2% | 73.39-34.1% | 111.37-9.0% | 122.34-19.9% | 152.79 | -51.86 | -24.30 |
| Total Shareholders Equity | 24.80-66.2% | 73.39-34.1% | 111.37-9.0% | 122.34-19.9% | 152.79+71.3% | 89.22+813.2% | 9.77 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 24.80-66.2% | 73.39-34.1% | 111.37-9.0% | 122.34-19.9% | 152.79+71.3% | 89.22+813.2% | 9.77 |
| Total Liabilities & Stockholders Equity | 69.40-46.4% | 129.50-25.9% | 174.83+9.1% | 160.25-10.6% | 179.25+85.9% | 96.40+344.6% | 21.68 |
| Book Value Per Share per share | 0.51-68.9% | 1.64-42.5% | 2.85-26.7% | 3.89-30.4% | 5.59 | -1.81 | -0.85 |
| Tangible Book Value Per Share per share | 0.51-68.9% | 1.64-42.5% | 2.85-26.7% | 3.89-30.4% | 5.59 | -1.81 | -0.85 |
| Full-Time Employees people | 39-15.2% | 46-2.1% | 47+2.2% | 46+17.9% | 39+62.5% | 24 | - |
| Price to Book Ratio ratio | 2.92 | 0.72 | 1.22 | 0.48 | 2.13 | 1.96 | - |
| Return on Assets % | -61.16 | -46.34 | -22.30 | -31.70 | -36.27 | -25.47 | - |
| Return on Equity % | -123.88 | -76.33 | -31.98 | -39.12 | -41.31 | -30.39 | - |
| Return on Invested Capital % | -187.21 | -64.74 | -24.10 | -39.88 | -29.86 | -16.51 | -52.25 |
| Quick Ratio ratio | 1.62 | 7.45 | 7.14 | 5.84 | 13.56 | 17.58 | 8.84 |
| Current Ratio ratio | 1.62 | 7.45 | 7.14 | 5.84 | 13.56 | 17.58 | 8.84 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -34.61 | -60.82 | -70.52 | -37.37 | -53.81 | -49.98 | -15.04 | -10.25 |
| Depreciation | 3.65 | 1.63-9.9% | 1.81+2.8% | 1.76-29.9% | 2.51+243.8% | 0.73-6.4% | 0.78+69.6% | 0.46 |
| Other Funds (Non Cash) | 6.19 | 7.10-28.9% | 9.99+12.4% | 8.89+10.0% | 8.08+97.6% | 4.09 | -6.67-802.1% | 0.95 |
| Funds from Operations | -24.77 | -52.09 | -58.71 | -26.72 | -43.22 | -45.15 | -20.93 | -8.83 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -5.38 | -8.21-424.5% | 2.53 | -5.89-331.9% | 2.54+11.4% | 2.28-1.3% | 2.31 | -0.71 |
| Cash from Operating Activities | -30.15 | -60.29 | -56.19 | -32.61 | -40.68 | -42.88 | -18.62 | -9.54 |
| Capital Expenditures | 0.00 | 0.00 | -0.25 | -0.77 | -3.61 | -0.50 | -0.56 | -0.27 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.42 | 0.00 | -0.25 | -0.77 | -3.61 | -0.50 | -0.56 | -0.27 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 5.64 | 6.03-74.6% | 23.75-59.4% | 58.43+265.4% | 15.99-85.4% | 109.43+16.4% | 94.01+329.1% | 21.91 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 5.64 | 6.03-74.6% | 23.75-59.4% | 58.43+265.4% | 15.99-85.4% | 109.43+16.4% | 94.01+329.1% | 21.91 |
| Proceedsfrom Stock Options | 5.64 | 6.03-74.6% | 23.72-59.4% | 58.42+271.2% | 15.74-85.6% | 109.22+16.2% | 93.99+329.0% | 21.91 |
| Issuance or Reduction of Debt, Net | -32.41 | 0.00 | -10.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -32.41 | 0.00 | -10.67 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00-100.0% | 29.33 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -32.41 | 0.00 | -40.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -26.77 | 6.03-53.9% | 13.08-77.6% | 58.43+265.4% | 15.99-85.4% | 109.43+16.6% | 93.86+328.4% | 21.91 |
| Net Change in Cash | -56.50 | -54.26 | -43.36-273.1% | 25.05 | -28.30-142.8% | 66.05-11.5% | 74.67+517.1% | 12.10 |
| Free Cash Flow | -30.15 | -60.29 | -56.44 | -33.38 | -44.30 | -43.37 | -19.18 | -9.81 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 21.99-71.7% | 46.45-49.5% | 57.05-48.6% | 65.71-46.5% | 77.60-42.6% | 92.04-33.9% | 111.00-17.4% | 122.83-5.7% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.46-92.2% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.91-68.0% | 2.28-5.8% | 1.54-25.6% | 2.46-3.1% | 2.84-3.4% | 2.42+4.3% | 2.07-22.8% | 2.54-17.5% |
| Total Current Assets | 22.89-71.5% | 48.73-48.4% | 58.59-48.2% | 68.17-45.8% | 80.44-42.0% | 94.46-33.6% | 113.07-18.3% | 125.83-9.6% |
| Net Property, Plant & Equipment | 1.26-88.7% | 9.29-20.7% | 9.90-19.6% | 10.51-18.8% | 11.11-17.3% | 11.71-16.6% | 12.32-17.0% | 12.94-17.0% |
| Total Investments and Advances | 0.00-100.0% | 0.00-100.0% | 0.90-26.2% | 0.90-26.2% | 0.90-25.6% | 0.89-95.8% | 1.22-94.2% | 1.22-94.2% |
| Intangible Assets | 0.00 | 0.00 | - | - | - | - | - | - |
| Deferred Tax Assets | - | - | - | - | - | - | 2.57 | - |
| Other Assets | 0.00-100.0% | 0.00-100.0% | 0.01-96.9% | 0.05+25.0% | 0.12-55.6% | 0.18-28.0% | 0.32-45.8% | 0.04-92.3% |
| Total Assets | 24.16-73.9% | 58.02-45.9% | 69.40-46.4% | 79.63-43.1% | 92.57-39.8% | 107.24-39.6% | 129.50-25.9% | 140.04-20.6% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00-100.0% | 30.43+2058.2% | 29.99+1822.4% | 7.50+468.2% | 3.85+203.1% | 1.41-89.1% | 1.56-81.2% | 1.32-59.6% |
| Accounts Payable | 1.94-30.0% | 3.57+260.6% | 0.75-75.3% | 1.08-12.9% | 2.77+88.4% | 0.99-37.7% | 3.04+126.9% | 1.24-10.8% |
| Other Current Liabilities | 5.92-30.7% | 4.51-51.3% | 5.41-48.9% | 9.02-8.9% | 8.54-1.8% | 9.27+37.9% | 10.59+8.4% | 9.90+1.2% |
| Total Current Liabilities | 7.86-48.2% | 38.52+230.1% | 36.15+138.1% | 17.60+41.3% | 15.17+32.6% | 11.67-45.0% | 15.18-21.7% | 12.46-13.7% |
| Long Term Debt | 0.00-100.0% | 7.22-79.7% | 7.68-78.4% | 29.80-16.0% | 33.29-6.0% | 35.60-7.2% | 35.53-18.6% | 35.46-27.5% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | - | - | - | 2.57 | - |
| Other Liabilities | 0.00-100.0% | 0.09-96.6% | 0.76-73.1% | 2.61-4.4% | 2.64-7.0% | 2.66+518.6% | 2.83+558.1% | 2.73+362.7% |
| Total Liabilities | 7.86-84.6% | 45.82-8.2% | 44.59-20.5% | 50.01-1.3% | 51.10+2.8% | 49.93-16.8% | 56.11-11.6% | 50.66-20.8% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 16.29-60.7% | 12.20-78.7% | 24.80-66.2% | 29.61-66.9% | 41.46-60.1% | 57.31-51.3% | 73.39-34.1% | 89.38-20.5% |
| Total Shareholders Equity | 16.29-60.7% | 12.20-78.7% | 24.80-66.2% | 29.61-66.9% | 41.46-60.1% | 57.31-51.3% | 73.39-34.1% | 89.38-20.5% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 16.29-60.7% | 12.20-78.7% | 24.80-66.2% | 29.61-66.9% | 41.46-60.1% | 57.31-51.3% | 73.39-34.1% | 89.38-20.5% |
| Total Liabilities & Stockholders Equity | 24.16-73.9% | 58.02-45.9% | 69.40-46.4% | 79.63-43.1% | 92.57-39.8% | 107.24-39.6% | 129.50-25.9% | 140.04-20.6% |
| Book Value Per Share per share | 0.34-62.6% | 0.25-80.5% | 0.51-68.9% | 0.63-69.1% | 0.91-61.8% | 1.28-52.9% | 1.64-42.5% | 2.04-35.2% |
| Tangible Book Value Per Share per share | 0.34-62.6% | 0.25-80.5% | 0.51-68.9% | 0.63-69.1% | 0.91-61.8% | 1.28-52.9% | 1.64-42.5% | 2.04-35.2% |
| Full-Time Employees people | - | 14-69.6% | 39-15.2% | - | 46 | 46 | 46-2.1% | - |
| Price to Book Ratio ratio | 2.92 | 1.63 | 1.01 | 2.15 | 0.85 | 0.59 | 0.72 | 0.89 |
| Return on Assets % | -59.31 | -68.09 | -61.16 | -66.32 | -59.40 | -50.84 | -46.34 | -39.26 |
| Return on Equity % | -119.86 | -161.89 | -123.88 | -122.43 | -100.55 | -82.81 | -76.33 | -61.56 |
| Return on Invested Capital % | 22.53 | -69.69 | -25.80 | -27.55 | -24.05 | -19.47 | -18.73 | -13.36 |
| Quick Ratio ratio | 2.91 | 1.27 | 1.62 | 3.87 | 5.30 | 8.09 | 7.45 | 10.10 |
| Current Ratio ratio | 2.91 | 1.27 | 1.62 | 3.87 | 5.30 | 8.09 | 7.45 | 10.10 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 3.67 | -13.53 | -8.38 | -16.37 | -17.98 | -18.09 | -20.40 | -16.67 |
| Depreciation | 2.45+497.6% | 0.40-7.0% | 0.40-9.1% | 0.40-11.1% | 0.41-8.9% | 0.43-6.5% | 0.44-4.3% | 0.45 |
| Other Funds (Non Cash) | 3.02+21.3% | 1.07-57.4% | 0.14-94.7% | 1.96-22.5% | 2.49+22.7% | 2.51-9.4% | 2.66+14.2% | 2.53-25.6% |
| Funds from Operations | 9.14 | -12.07 | -7.84 | -14.01 | -15.09 | -15.15 | -17.30 | -13.69 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -2.52 | 1.47 | -3.19-204.6% | -1.15-193.5% | -0.07-111.9% | -3.80 | 3.05-34.1% | 1.23 |
| Cash from Operating Activities | 6.63 | -10.60 | -11.02 | -15.16 | -15.16 | -18.95 | -14.25 | -12.46 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.12 | -0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Sale of Fixed Assets and Businesses | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.12 | -0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 0.00-100.0% | 0.00 | 2.37-7.1% | 3.27 | 0.39-58.9% | 0.00-100.0% | 2.55-71.9% | -0.01-125.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00-100.0% | 0.00 | 2.37-7.1% | 3.27 | 0.39-58.9% | 0.00-100.0% | 2.55-71.9% | -0.01-125.0% |
| Proceedsfrom Stock Options | 0.00-100.0% | 0.00 | 2.37-7.1% | 3.27 | 0.39-58.9% | 0.00-100.0% | 2.55-71.9% | -0.03-175.0% |
| Issuance or Reduction of Debt, Net | -32.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | -32.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -32.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | -32.41-8410.3% | 0.00 | 2.37-7.1% | 3.27 | 0.39 | 0.00-100.0% | 2.55-71.9% | -0.01-125.0% |
| Net Change in Cash | -25.37 | -10.60 | -8.66 | -11.88 | -14.78 | -18.95-490.7% | -11.83-375.8% | -12.47 |
| Free Cash Flow | 6.63 | -10.60 | -11.02 | -15.16 | -15.16 | -18.95 | -14.38 | -12.46 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 5.33% | 2.1M | 39.9M | 6.63M |
| 2026-10-15 | 5.90% | 2.4M | 39.9M | 6.69M |
| 2026-09-30 | 6.29% | 2.5M | 39.9M | 6.86M |
| 2026-09-15 | 4.02% | 1.7M | 42.5M | 7.02M |
| 2026-08-31 | 3.93% | 1.7M | 42.5M | 6.85M |
| 2026-08-14 | 2.51% | 1.1M | 42.5M | 720.93K |
| 2026-07-31 | 2.59% | 1.1M | 42.5M | 788.09K |
| 2026-07-15 | 2.20% | 0.9M | 42.5M | 690.68K |
| 2026-06-30 | 2.00% | 0.8M | 42.3M | 595.08K |
| 2026-06-15 | 2.29% | 1.0M | 42.2M | 456.51K |
| 2026-05-29 | 2.26% | 0.9M | 42.0M | 455.02K |
| 2026-05-15 | 1.61% | 0.7M | 41.5M | 447.42K |
| 2026-04-30 | 1.76% | 0.7M | 41.2M | 385.35K |
| 2026-04-15 | 1.95% | 0.8M | 40.4M | 421.34K |
| 2026-03-31 | 3.42% | 1.4M | 40.4M | 441.15K |
| 2026-03-13 | 3.47% | 1.4M | 40.4M | 631.40K |
| 2026-02-27 | 5.13% | 2.1M | 40.4M | 622.41K |
| 2026-02-13 | 5.08% | 2.1M | 40.4M | 618.62K |
| 2026-01-30 | 5.99% | 2.4M | 40.4M | 686.23K |
| 2026-01-15 | 5.66% | 2.3M | 40.4M | 720.07K |
Option chain
Expiry 2026-11-20 · underlying 1.01, quoted 13 Nov 08:16 ET · ATM 1.00
Option quotes 12 Nov 13:05 ET. A date on a row is older than the last session (12 Nov). 12 rows.
Implied move 34.65% into expiry (call 0.100 + put 0.250 = 0.350 on 1.01)
Put/call open interest 0.00 (0 puts / 1,189 calls) · Put/call volume 0.00 (0 puts / 6 calls)
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | ITM | 0.30 | 0.60 | 0.43 | -0.03 | - | 676 | 5 | 1 | 0.954 | -0.017 | 0.000 |
| put 1 Jan | OTM | 0.00 | 0.40 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.046 | -0.017 | 0.000 | |
| call | 1.00 | ATM | 0.00 | 0.20 | 0.14 | +0.06 | 366.5% -219.2 | 502 | 1 | 1 | 0.658 | -0.020 | 0.001 |
| put 1 Jan | ATM | 0.00 | 0.50 | 0.00 | 0.00 | 911.1% +325.5 | 0 | 0 | 0 | -0.342 | -0.020 | 0.001 | |
| call 28 Oct | 1.50 | OTM | 0.00 | 0.05 | 0.04 | 0.00 | - | 11 | 0 | 0 | 0.238 | -0.008 | 0.000 |
| put 1 Jan | ITM | 0.25 | 0.90 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.763 | -0.009 | 0.000 | |
| call 1 Jan | 2.00 | OTM | 0.00 | 0.60 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.195 | -0.011 | 0.000 |
| put 1 Jan | ITM | 0.75 | 1.40 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.805 | -0.010 | 0.000 | |
| call 1 Jan | 2.50 | OTM | 0.00 | 0.60 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.176 | -0.012 | 0.000 |
| put 1 Jan | ITM | 1.25 | 1.90 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.824 | -0.011 | 0.000 | |
| call 1 Jan | 5.00 | OTM | 0.00 | 0.60 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.143 | -0.015 | 0.000 |
| put 1 Jan | ITM | 3.70 | 4.40 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.857 | -0.014 | 0.000 | |
| call 1 Jan | 7.50 | OTM | 0.00 | 0.05 | 0.00 | 0.00 | - | 0 | 0 | 0 | 0.131 | -0.014 | 0.000 |
| put 1 Jan | ITM | 6.20 | 6.90 | 0.00 | 0.00 | - | 0 | 0 | 0 | -0.868 | -0.015 | 0.000 |
Latest SEC filings
30 of 455AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-07-31, period ended 2026-06-30. 10-K filed 2026-03-27, period ended 2025-12-31. HOWL on EDGAR
page 1 of 16Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-12 | EFFECT | SEC orders and notices | no report period | 9999999995-26-003522 index |
| 2026-11-12 | 424B3 | Registration statements and prospectuses | no report period | 0001140361-26-043455 index |
| 2026-11-10 | S-4/A | Registration statements and prospectuses | no report period | 0001140361-26-043046 index |
| 2026-11-10 | 425 | Registration statements and prospectuses | no report period | 0001140361-26-042855 index |
| 2026-11-09 | 8-K | All annual, quarterly, and current reports | 2026-11-09 | 0001193125-26-452789 index |
| 2026-10-26 | S-4/A | Registration statements and prospectuses | no report period | 0001140361-26-040784 index |
| 2026-09-22 | S-4 | Registration statements and prospectuses | no report period | 0001140361-26-037334 index |
| 2026-09-21 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0001732748-26-000003 index |
| 2026-08-21 | 425 | Registration statements and prospectuses | no report period | 0001193125-26-360063 index |
| 2026-08-21 | 8-K | All annual, quarterly, and current reports | 2026-08-21 | 0001193125-26-360059 index |
| 2026-08-20 | 8-K | All annual, quarterly, and current reports | 2026-08-14 | 0001193125-26-359185 index |
| 2026-07-31 | 10-Q | All annual, quarterly, and current reports | 2026-06-30 | 0001785530-26-000019 index |
| 2026-07-31 | 8-K | All annual, quarterly, and current reports | 2026-07-31 | 0001785530-26-000018 index |
| 2026-07-08 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-07-06 · transaction | 0001134657-26-000020 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047367 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047366 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047365 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047364 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047362 index |
| 2026-07-06 | 144 | no category | no report period | 0001628280-26-047360 index |
| 2026-07-02 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000187 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046087 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046086 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046085 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046084 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046083 index |
| 2026-06-29 | 144 | no category | no report period | 0001628280-26-046082 index |
| 2026-06-29 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-06-29 · transaction | 0001134657-26-000019 index |
| 2026-06-26 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000185 index |
| 2026-06-22 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000180 index |
Insider activity
as of 2026-07-07 · 100 filings| Insider | Title | Date | Type | Shares | Value ($) | Price | Remaining | Form 4 |
|---|---|---|---|---|---|---|---|---|
| EVNIN LUKE | Director | 2026-07-07 | Sale | 107,429 | 33,303 | 0.31 | 0 | Jul 08 05:34 PM |
| EVNIN LUKE | Director | 2026-07-06 | Sale | 35,770 | 11,446 | 0.32 | 107,429 | Jul 08 05:34 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-07-06 | Proposed Sale | 21,194 | 7,214 | 0.34 | - | Jul 06 05:19 PM |
| MPM Asset Management Investors | Shareholder | 2026-07-06 | Proposed Sale | 3,332 | 1,134 | 0.34 | - | Jul 06 05:19 PM |
| MPM Asset Management LLC | Shareholder | 2026-07-06 | Proposed Sale | 15,341 | 5,222 | 0.34 | - | Jul 06 05:19 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-07-06 | Proposed Sale | 80,142 | 27,280 | 0.34 | - | Jul 06 05:18 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-07-06 | Proposed Sale | 6,459 | 2,199 | 0.34 | - | Jul 06 05:18 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-07-06 | Proposed Sale | 96,873 | 32,976 | 0.34 | - | Jul 06 05:18 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-06-29 | Proposed Sale | 23,248 | 7,509 | 0.32 | - | Jun 29 05:30 PM |
| MPM Asset Management Investors | Shareholder | 2026-06-29 | Proposed Sale | 3,657 | 1,181 | 0.32 | - | Jun 29 05:30 PM |
| MPM Asset Management LLC | Shareholder | 2026-06-29 | Proposed Sale | 16,830 | 5,436 | 0.32 | - | Jun 29 05:29 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-06-29 | Proposed Sale | 87,916 | 28,397 | 0.32 | - | Jun 29 05:29 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-06-29 | Proposed Sale | 7,087 | 2,289 | 0.32 | - | Jun 29 05:29 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-06-29 | Proposed Sale | 106,262 | 34,323 | 0.32 | - | Jun 29 05:29 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-17 | Sale | 416,911 | 145,919 | 0.35 | 303,719 | Jun 22 06:59 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-12 | Sale | 170,441 | 68,176 | 0.40 | 349,907 | Jun 16 06:01 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-16 | Sale | 149,625 | 55,361 | 0.37 | 331,414 | Jun 16 06:01 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-15 | Sale | 128,770 | 50,220 | 0.39 | 341,353 | Jun 16 06:01 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-09 | Sale | 369,800 | 136,826 | 0.37 | 381,717 | Jun 11 08:13 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-11 | Sale | 262,503 | 99,751 | 0.38 | 361,229 | Jun 11 08:13 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-06-10 | Sale | 45,923 | 16,992 | 0.37 | 378,666 | Jun 11 08:13 PM |
| EVNIN LUKE | Director | 2026-06-09 | Sale | 76,928 | 28,463 | 0.37 | 300,283 | Jun 10 05:20 PM |
| EVNIN LUKE | Director | 2026-06-08 | Sale | 60,547 | 24,219 | 0.40 | 377,211 | Jun 08 06:13 PM |
| EVNIN LUKE | Director | 2026-06-05 | Sale | 24,946 | 9,978 | 0.40 | 437,758 | Jun 08 06:13 PM |
| EVNIN LUKE | Director | 2026-06-04 | Sale | 20,072 | 8,832 | 0.44 | 462,704 | Jun 08 06:13 PM |
| EVNIN LUKE | Director | 2026-06-01 | Sale | 80,459 | 37,816 | 0.47 | 542,120 | Jun 03 06:42 PM |
| EVNIN LUKE | Director | 2026-06-02 | Sale | 29,595 | 13,318 | 0.45 | 512,525 | Jun 03 06:42 PM |
| EVNIN LUKE | Director | 2026-06-03 | Sale | 29,749 | 12,495 | 0.42 | 482,776 | Jun 03 06:42 PM |
| EVNIN LUKE | Director | 2026-05-27 | Sale | 80,852 | 38,809 | 0.48 | 682,833 | May 29 06:51 PM |
| EVNIN LUKE | Director | 2026-05-29 | Sale | 32,556 | 14,650 | 0.45 | 622,579 | May 29 06:51 PM |
| EVNIN LUKE | Director | 2026-05-28 | Sale | 27,698 | 12,741 | 0.46 | 655,135 | May 29 06:51 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-05-28 | Proposed Sale | 244,185 | 119,651 | 0.49 | - | May 28 05:04 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-05-28 | Proposed Sale | 16,287 | 7,981 | 0.49 | - | May 28 05:03 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-05-28 | Proposed Sale | 202,029 | 98,994 | 0.49 | - | May 28 05:03 PM |
| MPM Asset Management LLC | Shareholder | 2026-05-28 | Proposed Sale | 38,675 | 18,951 | 0.49 | - | May 28 05:03 PM |
| MPM Asset Management Investors | Shareholder | 2026-05-28 | Proposed Sale | 8,405 | 4,118 | 0.49 | - | May 28 05:03 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-05-28 | Proposed Sale | 53,425 | 26,178 | 0.49 | - | May 28 05:02 PM |
| EVNIN LUKE | Director | 2026-05-22 | Sale | 87,425 | 39,341 | 0.45 | 831,635 | May 26 06:18 PM |
| EVNIN LUKE | Director | 2026-05-26 | Sale | 67,950 | 31,936 | 0.47 | 763,685 | May 26 06:18 PM |
| EVNIN LUKE | Director | 2026-05-21 | Sale | 36,387 | 15,283 | 0.42 | 919,060 | May 26 06:18 PM |
| EVNIN LUKE | Director | 2026-05-20 | Sale | 85,895 | 36,935 | 0.43 | 955,447 | May 20 06:08 PM |
| EVNIN LUKE | Director | 2026-05-19 | Sale | 62,970 | 28,336 | 0.45 | 1,041,342 | May 20 06:08 PM |
| EVNIN LUKE | Director | 2026-05-18 | Sale | 22,184 | 11,092 | 0.50 | 1,104,312 | May 20 06:08 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-05-18 | Proposed Sale | 63,540 | 32,729 | 0.52 | - | May 18 05:03 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-05-18 | Proposed Sale | 290,419 | 149,595 | 0.52 | - | May 18 05:02 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-05-18 | Proposed Sale | 19,370 | 9,977 | 0.52 | - | May 18 05:02 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-05-18 | Proposed Sale | 240,280 | 123,768 | 0.52 | - | May 18 05:02 PM |
| MPM Asset Management LLC | Shareholder | 2026-05-18 | Proposed Sale | 45,998 | 23,694 | 0.52 | - | May 18 05:01 PM |
| MPM Asset Management Investors | Shareholder | 2026-05-18 | Proposed Sale | 9,996 | 5,149 | 0.52 | - | May 18 05:01 PM |
| EVNIN LUKE | Director | 2026-05-13 | Sale | 44,679 | 24,127 | 0.54 | 1,126,496 | May 13 04:06 PM |
| EVNIN LUKE | Director | 2026-05-08 | Sale | 305,741 | 214,019 | 0.70 | 1,273,008 | May 12 07:47 PM |
| EVNIN LUKE | Director | 2026-05-12 | Sale | 67,885 | 43,446 | 0.64 | 1,171,175 | May 12 07:47 PM |
| EVNIN LUKE | Director | 2026-05-11 | Sale | 33,948 | 22,745 | 0.67 | 1,239,060 | May 12 07:47 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-05-08 | Sale | 376,526 | 267,333 | 0.71 | 418,813 | May 12 06:26 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-05-12 | Sale | 101,151 | 64,737 | 0.64 | 406,282 | May 12 06:26 PM |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner | 2026-05-11 | Sale | 87,490 | 58,618 | 0.67 | 413,001 | May 12 06:26 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-05-11 | Proposed Sale | 18,485 | 12,570 | 0.68 | - | May 11 04:33 PM |
| MPM Asset Management LLC | Shareholder | 2026-05-11 | Proposed Sale | 13,382 | 9,100 | 0.68 | - | May 11 04:33 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-05-11 | Proposed Sale | 84,491 | 57,454 | 0.68 | - | May 11 04:32 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-05-11 | Proposed Sale | 5,635 | 3,832 | 0.68 | - | May 11 04:32 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-05-11 | Proposed Sale | 69,904 | 47,535 | 0.68 | - | May 11 04:32 PM |
| MPM Asset Management Investors | Shareholder | 2026-05-11 | Proposed Sale | 2,908 | 1,977 | 0.68 | - | May 11 04:31 PM |
| EVNIN LUKE | Director | 2026-05-07 | Sale | 79,086 | 49,824 | 0.63 | 1,578,749 | May 07 06:22 PM |
| EVNIN LUKE | Director | 2026-05-06 | Sale | 14,635 | 9,659 | 0.66 | 1,657,835 | May 07 06:22 PM |
| EVNIN LUKE | Director | 2026-05-05 | Sale | 6,860 | 4,733 | 0.69 | 1,672,470 | May 07 06:22 PM |
| EVNIN LUKE | Director | 2026-04-30 | Sale | 168,262 | 121,149 | 0.72 | 1,785,687 | May 04 06:00 PM |
| EVNIN LUKE | Director | 2026-05-01 | Sale | 58,394 | 42,628 | 0.73 | 1,727,293 | May 04 06:00 PM |
| EVNIN LUKE | Director | 2026-05-04 | Sale | 47,963 | 34,533 | 0.72 | 1,679,330 | May 04 06:00 PM |
| MPM Asset Management Investors | Shareholder | 2026-05-01 | Proposed Sale | 12,515 | 9,006 | 0.72 | - | May 01 04:52 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-05-01 | Proposed Sale | 300,821 | 216,471 | 0.72 | - | May 01 04:52 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-05-01 | Proposed Sale | 24,251 | 17,451 | 0.72 | - | May 01 04:52 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-05-01 | Proposed Sale | 363,593 | 261,642 | 0.72 | - | May 01 04:51 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-05-01 | Proposed Sale | 79,549 | 57,243 | 0.72 | - | May 01 04:51 PM |
| MPM Asset Management LLC | Shareholder | 2026-05-01 | Proposed Sale | 57,588 | 41,440 | 0.72 | - | May 01 04:51 PM |
| EVNIN LUKE | Director | 2026-04-28 | Sale | 95,412 | 69,651 | 0.73 | 2,010,508 | Apr 29 07:16 PM |
| EVNIN LUKE | Director | 2026-04-27 | Sale | 53,940 | 45,849 | 0.85 | 2,105,920 | Apr 29 07:16 PM |
| EVNIN LUKE | Director | 2026-04-29 | Sale | 56,559 | 39,026 | 0.69 | 1,953,949 | Apr 29 07:16 PM |
| MPM Asset Management LLC | Shareholder | 2026-04-29 | Proposed Sale | 20,608 | 15,250 | 0.74 | - | Apr 29 04:48 PM |
| MPM Asset Management Investors | Shareholder | 2026-04-29 | Proposed Sale | 4,479 | 3,314 | 0.74 | - | Apr 29 04:48 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-04-29 | Proposed Sale | 107,652 | 79,662 | 0.74 | - | Apr 29 04:48 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-04-29 | Proposed Sale | 8,678 | 6,422 | 0.74 | - | Apr 29 04:47 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-04-29 | Proposed Sale | 130,115 | 96,285 | 0.74 | - | Apr 29 04:47 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-04-29 | Proposed Sale | 28,468 | 21,066 | 0.74 | - | Apr 29 04:47 PM |
| MPM Asset Management LLC | Shareholder | 2026-04-27 | Proposed Sale | 20,608 | 16,754 | 0.81 | - | Apr 27 05:01 PM |
| MPM Asset Management Investors | Shareholder | 2026-04-27 | Proposed Sale | 4,479 | 3,641 | 0.81 | - | Apr 27 05:01 PM |
| MPM BioVentures 2014 (B), L.P. | Shareholder | 2026-04-27 | Proposed Sale | 8,678 | 7,055 | 0.81 | - | Apr 27 05:00 PM |
| UBS Oncology Impact Fund, L.P. | Shareholder | 2026-04-27 | Proposed Sale | 107,652 | 87,521 | 0.81 | - | Apr 27 05:00 PM |
| MPM BioVentures 2014, L.P. | Shareholder | 2026-04-27 | Proposed Sale | 130,115 | 105,784 | 0.81 | - | Apr 27 05:00 PM |
| MPM Oncology Innovations Fund, | Shareholder | 2026-04-27 | Proposed Sale | 28,468 | 23,144 | 0.81 | - | Apr 27 04:59 PM |
| EVNIN LUKE | Director | 2026-01-16 | Sale | 38,782 | 20,942 | 0.54 | 2,159,860 | Jan 20 04:07 PM |
| EVNIN LUKE | Director | 2026-01-13 | Sale | 43,198 | 23,759 | 0.55 | 2,266,671 | Jan 15 05:22 PM |
| EVNIN LUKE | Director | 2026-01-15 | Sale | 37,413 | 20,577 | 0.55 | 2,198,642 | Jan 15 05:22 PM |
| EVNIN LUKE | Director | 2026-01-14 | Sale | 30,616 | 17,451 | 0.57 | 2,236,055 | Jan 15 05:22 PM |
| EVNIN LUKE | Director | 2026-01-12 | Sale | 58,980 | 33,619 | 0.57 | 2,309,869 | Jan 12 05:09 PM |
| EVNIN LUKE | Director | 2026-01-09 | Sale | 24,678 | 15,054 | 0.61 | 2,368,849 | Jan 12 05:09 PM |
| EVNIN LUKE | Director | 2026-01-08 | Sale | 7,716 | 4,861 | 0.63 | 2,393,527 | Jan 12 05:09 PM |
| EVNIN LUKE | Director | 2026-01-06 | Sale | 40,761 | 26,495 | 0.65 | 2,413,158 | Jan 07 05:12 PM |
| EVNIN LUKE | Director | 2026-01-05 | Sale | 18,378 | 11,762 | 0.64 | 2,453,919 | Jan 07 05:12 PM |
| EVNIN LUKE | Director | 2026-01-07 | Sale | 11,915 | 7,626 | 0.64 | 2,401,243 | Jan 07 05:12 PM |
| MPM Asset Management LLC | Shareholder | 2026-01-06 | Proposed Sale | 31,458 | 20,272 | 0.64 | - | Jan 06 04:59 PM |
Monthly total
as of 2026-11 · feed totals, not a recount of the rows above| Month | Bought ($) | Buys | Sold ($) | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 44,749 | 2 |
| 2026-06 | 0 | 0 | 708,366 | 14 |
| 2026-05 | 0 | 0 | 1,065,527 | 21 |
| 2026-04 | 0 | 0 | 275,674 | 4 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 193,843 | 11 |
| 2025-12 | 0 | 0 | 1,092,727 | 28 |
| 2025-11 | 0 | 0 | 3,344,832 | 57 |
Institutional holders
as of quote 2026-11-13. 13F filing period is not in this feed — not a live holding. 10 managers, 18.81% of shares, of 22.67% institutional Overlap: Vanguard is on both cards (1 manager, 2 funds). Do not add them.| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 4.91% |
| BALYASNY ASSET MANAGEMENT L.P. | 3.68% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.51% |
| Lynx1 Capital Management LP | 1.35% |
| SPHERA FUNDS MANAGEMENT LTD. | 1.29% |
| DC Funds, LP | 1.21% |
| JANE STREET GROUP, LLC | 1.16% |
| RENAISSANCE TECHNOLOGIES LLC | 1.13% |
| GEODE CAPITAL MANAGEMENT, LLC | 0.84% |
| Verdad Advisers, LP | 0.72% |
Funds
as of quote 2026-11-13. 13F filing period is not in this feed — not a live holding. 9 funds, 20.11% of shares, of 22.67% institutional Overlap: Vanguard is on both cards (1 manager, 2 funds). Do not add them.| Fund | Kind | % owned |
|---|---|---|
| Select Biotechnology Portfolio | not named | 16.96% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | mutual fund | 1.80% |
| VANGUARD EXTENDED MARKET INDEX FUND | mutual fund | 0.71% |
| Fidelity Extended Market Index Fund | mutual fund | 0.42% |
| Fidelity Total Market Index Fund | mutual fund | 0.11% |
| Fidelity Series Total Market Index Fund | mutual fund | 0.09% |
| Fidelity Nasdaq Composite Index Fund | mutual fund | 0.02% |
| Blackstone Alternative Multi-Strategy Fund | mutual fund | 0.00% |
| Guggenheim Active Allocation Fund | mutual fund | 0.00% |
OakChart. HOWL. Cached 15 minutes. Terms